Elliot Chartash
Impact in
- Rheumatology top 0.1%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Immunology 23
- T-cell and B-cell Immunology 9
- Immunotherapy and Immune Responses 9
- Oncology 22
- Cancer Immunotherapy and Biomarkers 20
- CAR-T cell therapy research 11
- Co-authors
- Steven Fischkoff (4 shared papers)Edward Keystone (3 shared papers)Daniel E. Furst (3 shared papers)C. Birbara (2 shared papers)Larry W. Moreland (2 shared papers)Michael E. Weinblatt (2 shared papers)Michael H. Weisman (2 shared papers)Leah Teoh (2 shared papers)
- Journals
- Annals of Oncology (7 papers)Journal of Clinical Oncology (5 papers)Cancer Research (4 papers)Seminars in Arthritis and Rheumatism (3 papers)Journal of Clinical Investigation (2 papers)
- Partner nations
- United StatesIsraelAustralia
In The Last Decade
Elliot Chartash
47 papers receiving 4.6k citations
Elliot Chartash's Hit Papers
Peers
Comparison fields: 5 of 112
- Rheumatology 3.0k
- Hematology 1.5k
- Immunology 1.4k
- Genetics 601
- Oncology 792
Countries citing papers authored by Elliot Chartash
This map shows the geographic impact of Elliot Chartash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliot Chartash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliot Chartash more than expected).
Fields of papers citing papers by Elliot Chartash
This network shows the impact of papers produced by Elliot Chartash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliot Chartash. The network helps show where Elliot Chartash may publish in the future.
Co-authors
The 25 scholars most cited alongside Elliot Chartash, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Hit paper breakdown → | 2003 | 1413 |
| 2 | Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial Hit paper breakdown → | 2004 | 956 |
| 3 | Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). | 2003 | 409 |
| 4 | Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. | 2005 | 409 |
| 5 | 2003 | 224 | |
| 6 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ Hit paper breakdown → | 2021 | 196 |
| 7 | 1989 | 110 | |
| 8 | 2020 | 106 | |
| 9 | 1996 | 84 | |
| 10 | 1992 | 81 | |
| 11 | Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. | 2008 | 56 |
| 12 | 1994 | 55 | |
| 13 | 2014 | 51 | |
| 14 | 1999 | 48 | |
| 15 | 2020 | 47 | |
| 16 | 2020 | 46 | |
| 17 | 1999 | 41 | |
| 18 | 1988 | 37 | |
| 19 | 1989 | 31 | |
| 20 | 2004 | 27 |
About Elliot Chartash
Elliot Chartash is a scholar working on Immunology, Oncology, Rheumatology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 49 papers that have together received 4.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (11 papers), T-cell and B-cell Immunology (9 papers), Immunotherapy and Immune Responses (9 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Rheumatoid Arthritis Research and Therapies (8 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). The work is most often cited by research in Rheumatology (3.0k citations), Hematology (1.5k citations), Immunology (1.4k citations), Genetics (601 citations) and Oncology (792 citations). Elliot Chartash has collaborated with scholars based in United States, Israel and Australia. Frequent co-authors include Steven Fischkoff, Edward Keystone, Daniel E. Furst, C. Birbara, Larry W. Moreland, Michael E. Weinblatt, Michael H. Weisman, Leah Teoh, Arthur F. Kavanaugh and H Tannenbaum. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancer Research, Seminars in Arthritis and Rheumatism and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.